cagrisema novo nordisk news - Search News

Novo Nordisk Shares Fall

Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Barron's on MSN · 7h

Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly.

Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug CagriSema.It turns out the company was wrong.On Friday, Novo released the results of a large Phase 3 trial of the drug.

New York Post on MSN · 11h

Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.

7hon MSN

BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.

14h

Novo Nordisk: Why The Market Sell-Off On CagriSema Data May Be Justified

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

12h

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results